All news

22 October 2026

A bipartisan bill wants drug trials to come to patients, not the other way round

Reps. Jake Auchincloss and Morgan Griffith introduced the Faster Clinical Trials Act, which aims to cut the cost and enrollment time of drug trials by at least 30%.

Testing a new drug usually means asking patients to travel to a big medical center. For people with rare diseases, some of which may affect only a few dozen people, simply finding enough of them is a major hurdle. A new bill in Congress tries to flip the model around.

What happened

Democratic Rep. Jake Auchincloss of Massachusetts and Republican Rep. Morgan Griffith of Virginia introduced the Faster Clinical Trials Act on Thursday. It arrived a week after the Food and Drug Administration announced its own Rare Disease Framework Initiative, promising more flexibility when judging treatments for small patient groups.

The bill's main ideas:

  • A new Center for Clinical Trial Innovation at the FDA to run networks of reusable trial sites, instead of building and tearing down a fresh setup for every study.
  • "Point-of-care" trials, where patients get an experimental drug at their usual doctor's office and are tracked by video calls, electronic health records or wearable devices.
  • Encouragement for drugmakers to use computer simulations in early-stage research, and fixes for common reasons the FDA pauses trials.
  • Up to $75 million a year for the FDA over five years, with a goal of cutting trial costs and enrollment time by at least 30%.

Griffith said the change would help people beyond rare diseases, such as constituents in southwest Virginia with black lung disease who live two hours or more from a trial center. Duke University's Duke-Margolis Institute for Health Policy helped draft the bill.

Why it matters

Clinical trials are one of the slowest and most expensive steps in getting a drug to market, and a big reason drugs take so long to reach pharmacy shelves. Cheaper, faster trials could matter most for small biotech companies, which often have limited cash to fund them. The idea is not brand new: the Department of Veterans Affairs ran the first point-of-care trial in 2010, and the approach is widely used in Australia, but it never caught on in the US.

There are limits. Intensive treatments such as gene therapies will still need academic medical centers, said Mark McClellan, founding director of Duke-Margolis. Auchincloss described the plan as having "something in here for everyone to like", from drugmakers to patient groups.

What to watch

  • Timing: Griffith said a House vote likely won't happen until next year.
  • A Senate version, which Auchincloss's office says a bipartisan group plans to introduce later this year.
  • How the bill fits with the FDA's new rare disease framework.

Based on reporting by CNBC: Bipartisan bill aims to speed up trials for rare disease treatments. Facts, not advice.

More news